The Study
Blockade of A2AR improved brain perfusion and cognitive function in a mouse model of Alzheimer’s disease
This study tested a drug on a small group of sick mice to see if it helped their brains work better. It found some changes, like better blood flow and memory, but it’s only in mice—not people—and only in one type of mouse. So we can’t say it will work in humans.
Analysis score
Maximum 90 for a randomized controlled trial.
Where the score came from
Scientists gave a special drug to older female mice that have brain changes like Alzheimer’s disease. The drug blocked a brain signal that was making blood flow too low and causing memory problems.
Where does this study sit?
Reviews of RCTs (Meta-analyses)
Max 100Randomized Trials
Max 90Reviews of Cohort Studies
Max 85Cohort Studies
Max 72Reviews of Case-Control Studies
Max 63Case-Control Studies
Max 58Cross-Sectional & Case Series
Max 50Expert Opinion
Max 516 / 100
Quality score
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Key takeaways
Summary
Based on the study abstract and findings.
- 1Yes — restoring blood flow and reducing Alzheimer’s proteins in mice suggests this drug could potentially help protect the brain from damage and improve memory in humans with Alzheimer’s, especially women.
- 2The drug increased brain blood flow by 51%, reduced Alzheimer’s proteins (APP by 38%, tau by 28%), lowered harmful chemicals (PRMT4 by 52%, ADMA by 50%), fixed brain barrier proteins (occludin +45%, ZO-1 +30%), and improved memory (T-maze +10%, new object exploration +3.5x).
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
GeroScience
Year
2025
Authors
Mariana Sayuri Berto Udo, Julia Zaccarelli-Magalhães, Garrett A Clemons, C. Citadin, Julia Langman, D. Smith, Luiz Henrique Matuguma, Vesna Tesic, Hung Wen Lin
Related Content
Claims (6)
In aged female 3xTg mice, 7 days of istradefylline treatment reduces cortical PRMT4 protein levels by 52% and ADMA levels by 50%, returning both to levels seen in healthy aged C57BL/6 mice.
In aged female mice with Alzheimer’s-like brain changes, 7 days of istradefylline treatment improved performance on memory tests, bringing their performance to the level of healthy aged mice.
Caffeine blocks adenosine receptors in the brain and reduces amyloid plaque accumulation.
In aged female 3xTg mice, a 7-day injection of istradefylline at 2 mg/kg/day increases cortical cerebral blood flow by 51%, bringing blood flow levels up to those seen in healthy aged mice and young mice with the same genetic model.
In aged female mice with Alzheimer’s-like pathology, 7 days of istradefylline treatment increased levels of two proteins, occludin and ZO-1, in the brain’s blood vessels to match levels seen in healthy aged mice.
In aged female 3xTg mice, 7 days of istradefylline treatment reduces cortical amyloid precursor protein levels by 38% and total tau protein levels by 28%, bringing them to levels observed in young 3xTg mice.
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.